Phaseline

Companies › Huons Biopharma

Huons Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HU-045
Botulinum toxin type A; cleaves SNAP25 to block acetylcholine release at the neuromuscular
SNAP25Phase 3Glabellar LinesMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07870694HU-045Phase 3Glabellar LinesOtherMay 2027

Targets

SNAP25 (1)

Companies with the same targets

AbbVie Biojiva Merz Therapeutics Ipsen Merz Aesthetics Merz Pharmaceuticals Merz North America

Companies built like this

Merz Aesthetics Merz North America Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.